Form 4: BeiGene CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 64,628 shares of common stock on July 17, 2026.

Summary

  • Option exercise/conversion: acquired 64,628 American Depositary Shares at $119.96 ($7,752,775) on July 17, 2026; holds 64,628 after (Direct).
  • Open-market sale: disposed of 1,440 American Depositary Shares at $305.20 ($439,486) on July 17, 2026; holds 63,188 after (Direct).
  • Open-market sale: disposed of 597 American Depositary Shares at $306.96 ($183,258) on July 17, 2026; holds 62,591 after (Direct).
  • Open-market sale: disposed of 680 American Depositary Shares at $309.05 ($210,157) on July 17, 2026; holds 61,911 after (Direct).
  • Open-market sale: disposed of 4,833 American Depositary Shares at $310.37 ($1,500,015) on July 17, 2026; holds 57,078 after (Direct).
  • Open-market sale: disposed of 5,543 American Depositary Shares at $311.42 ($1,726,218) on July 17, 2026; holds 51,535 after (Direct).
  • Open-market sale: disposed of 35,829 American Depositary Shares at $312.17 ($11,184,911) on July 17, 2026; holds 15,706 after (Direct).
  • Open-market sale: disposed of 14,915 American Depositary Shares at $313.19 ($4,671,198) on July 17, 2026; holds 791 after (Direct).
  • Open-market sale: disposed of 740 American Depositary Shares at $314.32 ($232,597) on July 17, 2026; holds 51 after (Direct).
  • Open-market sale: disposed of 51 American Depositary Shares at $315.06 ($16,068) on July 17, 2026 (Direct).
  • Option exercise/conversion: disposed of 840,164 Share Option (Right to Buy) on July 17, 2026; holds 441,870 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $20,163,907 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

John Oyler — Director, Officer (Chief Executive Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-17Option exercise/conversionAmerican Depositary Shares64,628$120$7.8M64,628
2026-07-17Open-market saleAmerican Depositary Shares1,440$305$439.5K63,188
2026-07-17Open-market saleAmerican Depositary Shares597$307$183.3K62,591
2026-07-17Open-market saleAmerican Depositary Shares680$309$210.2K61,911
2026-07-17Open-market saleAmerican Depositary Shares4,833$310$1.5M57,078
2026-07-17Open-market saleAmerican Depositary Shares5,543$311$1.7M51,535
2026-07-17Open-market saleAmerican Depositary Shares35,829$312$11.2M15,706
2026-07-17Open-market saleAmerican Depositary Shares14,915$313$4.7M791
2026-07-17Open-market saleAmerican Depositary Shares740$314$232.6K51
2026-07-17Open-market saleAmerican Depositary Shares51$315$16.1K0
2026-07-17Option exercise/conversionShare Option (Right to Buy)840,164——441,870

Key Dates

DateDescription
2026-07-17Option exercise/conversion (64,628 shares)
2026-07-17Open-market sale (1,440 shares)
2026-07-17Open-market sale (597 shares)
2026-07-17Open-market sale (680 shares)
2026-07-17Open-market sale (4,833 shares)
2026-07-17Open-market sale (5,543 shares)
2026-07-17Open-market sale (35,829 shares)
2026-07-17Open-market sale (14,915 shares)
2026-07-17Open-market sale (740 shares)
2026-07-17Open-market sale (51 shares)
2026-07-17Option exercise/conversion (840,164 shares)

Keywords

insider transaction, Form 4, ONC, BeOne Medicines Ltd., bearish, John Oyler

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.